Xpovio, Nexpovio(selinexor)
Nexpovio, Xpovio (selinexor) is a small molecule pharmaceutical. Selinexor was first approved as Xpovio on 2019-07-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target exportin-1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Xpovio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selinexor
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XPOVIO | Karyopharm Therapeutics | N-212306 RX | 2019-07-03 | 4 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xpovio | New Drug Application | 2022-07-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SELINEXOR, XPOVIO, KARYOPHARM THERAPS | |||
| 2027-12-18 | ODE*, ODE-346 | ||
| 2027-06-22 | ODE*, ODE-310 | ||
| 2026-07-03 | ODE*, ODE-257 | ||
| 2024-07-03 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Selinexor, Xpovio, Karyopharm Theraps | |||
| 10519139 | 2035-08-14 | DS, DP | U-2584, U-2855, U-3018 |
| 11746102 | 2035-08-14 | U-2584, U-2855, U-3018 | |
| 11753401 | 2035-08-14 | DP | U-2584, U-2855, U-3018 |
| 11807629 | 2035-08-14 | DS, DP | |
| 8999996 | 2033-07-03 | DS, DP | |
| 9079865 | 2032-07-26 | U-2584, U-2855, U-3018 | |
| 9714226 | 2032-07-26 | DS, DP | |
| 10544108 | 2032-07-26 | U-2584, U-3018 | |
| 11034660 | 2032-07-26 | U-2584, U-3018 | |
| 11787771 | 2032-07-26 | U-2584, U-2855, U-3018 | |
HCPCS
No data
Clinical
Clinical Trials
169 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 7 | 17 | 2 | — | — | 21 |
| Plasma cell neoplasms | D054219 | — | — | 7 | 17 | 2 | — | — | 21 |
| Lymphoma | D008223 | — | C85.9 | 5 | 5 | 1 | — | — | 9 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 3 | 1 | — | — | 6 |
| Carcinoma | D002277 | — | C80.0 | 3 | 4 | 1 | — | — | 6 |
| B-cell lymphoma | D016393 | — | — | 3 | 3 | 1 | — | — | 5 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 3 | 1 | — | — | 4 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 1 | 2 | — | — | 3 |
| Liposarcoma | D008080 | — | — | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 9 | 5 | — | — | — | 12 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 9 | 5 | — | — | — | 12 |
| Myeloid leukemia | D007951 | — | C92 | 7 | 5 | — | — | — | 10 |
| Neoplasms | D009369 | — | C80 | 5 | 2 | — | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 4 | — | — | — | 4 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | — | — | — | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | — | — | — | 3 |
| Preleukemia | D011289 | — | — | 1 | 2 | — | — | — | 3 |
| Syndrome | D013577 | — | — | 1 | 2 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 2 |
Show 35 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 3 | — | — | — | — | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | — | — | — | — | 2 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
| Recurrence | D012008 | — | — | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Aggression | D000374 | EFO_0003015 | — | 1 | — | — | — | — | 1 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Blast crisis | D001752 | — | — | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Selinexor |
| INN | selinexor |
| Description | Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.
|
| Classification | Small molecule |
| Drug class | exportin 1 inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1 |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545185 |
| ChEBI ID | — |
| PubChem CID | 71481097 |
| DrugBank | DB11942 |
| UNII ID | 31TZ62FO8F (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
XPO1
XPO1
Organism
Homo sapiens
Gene name
XPO1
Gene synonyms
CRM1
NCBI Gene ID
Protein name
exportin-1
Protein synonyms
chromosome region maintenance 1 homolog, Chromosome region maintenance 1 protein homolog, exportin 1 (CRM1 homolog, yeast), exportin-1 (required for chromosome region maintenance)
Uniprot ID
Mouse ortholog
Xpo1 (103573)
exportin-1 (Q6P5F9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,236 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,551 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use